Search Results - "Antineoplastic Combined Chemotherapy Protocols"

Neoadjuvant chemoradiotherapy with capecitabine and irinotecan guided by UGT1A1 status in patients with locally advanced rectal cancer: 5-year update of the CinClare trial.

Authors: Zhang Z Sun X Liu A et al.

Source: Cancer communications (London, England) [Cancer Commun (Lond)] 2025 Nov; Vol. 45 (11), pp. 1417-1430. Date of Electronic Publication: 2025 Sep 03.

Publication Type: Journal Article; Randomized Controlled Trial; Clinical Trial, Phase III; Multicenter Study

Journal Info: Publisher: Wiley Country of Publication: United States NLM ID: 101723675 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2523-3548 (Electronic) Linking ISSN: 25233548 NLM ISO Abbreviation: Cancer Commun (Lond) Subsets: MEDLINE

MeSH Terms: Glucuronosyltransferase*/genetics , Irinotecan*/administration & dosage , Irinotecan*/therapeutic use , Rectal Neoplasms*/therapy , Rectal Neoplasms*/genetics , Rectal Neoplasms*/mortality , Rectal Neoplasms*/pathology , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use , Antineoplastic Combined Chemotherapy Protocols*/adverse effects, Humans ; Male ; Capecitabine/administration & dosage ; Capecitabine/therapeutic use ; Middle Aged ; Female ; Neoadjuvant Therapy/methods ; Aged ; Adult ; Genotype ; Chemoradiotherapy ; Follow-Up Studies ; Treatment Outcome

Potential therapeutic GSK-3β inhibitor 9-ING-41 is active in combination with venetoclax in double-hit lymphoma (DHL).

Authors: Lei H Zhang Y Zheng H et al.

Source: Cancer biology & therapy [Cancer Biol Ther] 2025 Dec 31; Vol. 26 (1), pp. 2581831. Date of Electronic Publication: 2025 Nov 11.

Publication Type: Journal Article

Journal Info: Publisher: Taylor & Francis Country of Publication: United States NLM ID: 101137842 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1555-8576 (Electronic) Linking ISSN: 15384047 NLM ISO Abbreviation: Cancer Biol Ther Subsets: MEDLINE

MeSH Terms: Sulfonamides*/pharmacology , Sulfonamides*/therapeutic use , Bridged Bicyclo Compounds, Heterocyclic*/pharmacology , Bridged Bicyclo Compounds, Heterocyclic*/therapeutic use , Glycogen Synthase Kinase 3 beta*/antagonists & inhibitors , Antineoplastic Combined Chemotherapy Protocols*/pharmacology , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use , Lymphoma*/drug therapy , Lymphoma*/pathology , Lymphoma*/genetics, Humans ; Cell Line, Tumor ; Apoptosis/drug effects ; Cell Proliferation/drug effects ; Drug Synergism ; Cell Survival/drug effects

Metformin with neoadjuvant chemotherapy in localized triple-negative and Her2neu-positive breast cancer: A prospective phase 2 open-label randomized controlled trial (McBETH).

Authors: Mouna BM Batra A Sharma V et al.

Source: Cancer [Cancer] 2025 Dec 15; Vol. 131 (24), pp. e70205.

Publication Type: Journal Article; Clinical Trial, Phase II; Randomized Controlled Trial

Journal Info: Publisher: Wiley Country of Publication: United States NLM ID: 0374236 Publication Model: Print Cited Medium: Internet ISSN: 1097-0142 (Electronic) Linking ISSN: 0008543X NLM ISO Abbreviation: Cancer Subsets: MEDLINE

MeSH Terms: Metformin*/administration & dosage , Metformin*/adverse effects , Metformin*/therapeutic use , Neoadjuvant Therapy*/methods , Receptor, ErbB-2*/metabolism , Triple Negative Breast Neoplasms*/drug therapy , Triple Negative Breast Neoplasms*/pathology , Triple Negative Breast Neoplasms*/metabolism , Triple Negative Breast Neoplasms*/surgery , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use , Antineoplastic Combined Chemotherapy Protocols*/adverse effects, Humans ; Female ; Middle Aged ; Adult ; Aged ; Prospective Studies ; Young Adult ; Adolescent ; Treatment Outcome ; Chemotherapy, Adjuvant

Five-Year Outcomes of the POLARIX Study Comparing Pola-R-CHP and R-CHOP in Patients With Diffuse Large B-Cell Lymphoma.

Authors: Morschhauser F Salles G Sehn LH et al.

Source: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2025 Dec 10; Vol. 43 (35), pp. 3698-3705. Date of Electronic Publication: 2025 Sep 24.

Publication Type: Journal Article; Multicenter Study; Comparative Study; Randomized Controlled Trial; Clinical Trial, Phase III

Journal Info: Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 8309333 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1527-7755 (Electronic) Linking ISSN: 0732183X NLM ISO Abbreviation: J Clin Oncol Subsets: MEDLINE

MeSH Terms: Lymphoma, Large B-Cell, Diffuse*/drug therapy , Lymphoma, Large B-Cell, Diffuse*/mortality , Lymphoma, Large B-Cell, Diffuse*/pathology , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use , Antineoplastic Combined Chemotherapy Protocols*/adverse effects , Antineoplastic Combined Chemotherapy Protocols*/administration & dosage, Humans ; Cyclophosphamide/administration & dosage ; Cyclophosphamide/adverse effects ; Cyclophosphamide/therapeutic use ; Doxorubicin/administration & dosage ; Doxorubicin/adverse effects ; Doxorubicin/therapeutic use ; Vincristine/administration & dosage ; Vincristine/adverse effects ; Vincristine/therapeutic use ; Prednisone/administration & dosage ; Prednisone/adverse effects ; Prednisone/therapeutic use ; Rituximab/administration & dosage ; Rituximab/adverse effects ; Middle Aged ; Male ; Female ; Aged ; Adult ; Progression-Free Survival ; Antibodies, Monoclonal, Humanized/administration & dosage ; Antibodies, Monoclonal, Humanized/adverse effects ; Aged, 80 and over ; Young Adult ; Antibodies, Monoclonal ; Immunoconjugates

Updated Overall Survival Analysis From the Phase II PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic Non-Small Cell Lung Cancer.

Authors: Johnson ML Smit EF Felip E et al.

Source: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2025 Dec 10; Vol. 43 (35), pp. 3706-3713. Date of Electronic Publication: 2025 Oct 19.

Publication Type: Journal Article; Clinical Trial, Phase II; Multicenter Study

Journal Info: Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 8309333 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1527-7755 (Electronic) Linking ISSN: 0732183X NLM ISO Abbreviation: J Clin Oncol Subsets: MEDLINE

MeSH Terms: Proto-Oncogene Proteins B-raf*/genetics , Lung Neoplasms*/drug therapy , Lung Neoplasms*/genetics , Lung Neoplasms*/pathology , Lung Neoplasms*/mortality , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use , Antineoplastic Combined Chemotherapy Protocols*/adverse effects , Carcinoma, Non-Small-Cell Lung*/drug therapy , Carcinoma, Non-Small-Cell Lung*/genetics , Carcinoma, Non-Small-Cell Lung*/mortality , Carcinoma, Non-Small-Cell Lung*/pathology, Humans ; Benzimidazoles/administration & dosage ; Benzimidazoles/adverse effects ; Carbamates/administration & dosage ; Carbamates/adverse effects ; Sulfonamides/administration & dosage ; Sulfonamides/adverse effects ; Female ; Male ; Middle Aged ; Aged ; Mutation ; Adult ; Survival Analysis

TRYBECA-1: A Randomized Phase III Study of Eryaspase Combined With Chemotherapy Versus Chemotherapy as Second-Line Treatment in Patients With Advanced Pancreatic Adenocarcinoma.

Authors: Hammel P Metges JP Macarulla Mercade T et al.

Source: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2025 Dec 10; Vol. 43 (35), pp. 3714-3727. Date of Electronic Publication: 2025 Nov 04.

Publication Type: Journal Article; Randomized Controlled Trial; Clinical Trial, Phase III; Multicenter Study

Journal Info: Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 8309333 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1527-7755 (Electronic) Linking ISSN: 0732183X NLM ISO Abbreviation: J Clin Oncol Subsets: MEDLINE

MeSH Terms: Antineoplastic Combined Chemotherapy Protocols*/therapeutic use , Antineoplastic Combined Chemotherapy Protocols*/adverse effects , Pancreatic Neoplasms*/drug therapy , Pancreatic Neoplasms*/pathology , Pancreatic Neoplasms*/mortality , Carcinoma, Pancreatic Ductal*/drug therapy , Carcinoma, Pancreatic Ductal*/pathology , Carcinoma, Pancreatic Ductal*/mortality , Adenocarcinoma*/drug therapy , Adenocarcinoma*/pathology, Humans ; Male ; Female ; Middle Aged ; Aged ; Irinotecan/administration & dosage ; Irinotecan/adverse effects ; Fluorouracil/administration & dosage ; Fluorouracil/adverse effects ; Gemcitabine ; Deoxycytidine/analogs & derivatives ; Deoxycytidine/administration & dosage ; Deoxycytidine/adverse effects ; Leucovorin/administration & dosage ; Leucovorin/adverse effects ; Adult ; Paclitaxel/administration & dosage ; Paclitaxel/adverse effects ; Albumins/administration & dosage ; Albumins/adverse effects ; Progression-Free Survival

A targeted combination therapy achieves effective pancreatic cancer regression and prevents tumor resistance.

Authors: Liaki V Barrambana S Kostopoulou M et al.

Source: Proceedings of the National Academy of Sciences of the United States of America [Proc Natl Acad Sci U S A] 2025 Dec 09; Vol. 122 (49), pp. e2523039122. Date of Electronic Publication: 2025 Dec 02.

Publication Type: Journal Article

Journal Info: Publisher: National Academy of Sciences Country of Publication: United States NLM ID: 7505876 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1091-6490 (Electronic) Linking ISSN: 00278424 NLM ISO Abbreviation: Proc Natl Acad Sci U S A Subsets: MEDLINE

MeSH Terms: Pancreatic Neoplasms*/drug therapy , Pancreatic Neoplasms*/genetics , Pancreatic Neoplasms*/pathology , Pancreatic Neoplasms*/metabolism , Carcinoma, Pancreatic Ductal*/drug therapy , Carcinoma, Pancreatic Ductal*/genetics , Carcinoma, Pancreatic Ductal*/pathology , Drug Resistance, Neoplasm*/drug effects , Antineoplastic Combined Chemotherapy Protocols*/pharmacology , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use, Animals ; Humans ; Mice ; STAT3 Transcription Factor/antagonists & inhibitors ; STAT3 Transcription Factor/metabolism ; STAT3 Transcription Factor/genetics ; Proto-Oncogene Proteins p21(ras)/genetics ; Proto-Oncogene Proteins p21(ras)/antagonists & inhibitors ; Proto-Oncogene Proteins p21(ras)/metabolism ; Cell Line, Tumor ; Xenograft Model Antitumor Assays ; ErbB Receptors/antagonists & inhibitors ; ErbB Receptors/metabolism ; ErbB Receptors/genetics ; Signal Transduction/drug effects ; Molecular Targeted Therapy ; Tumor Suppressor Protein p53/genetics

Health economic outcomes and costs of CDK4/6 inhibitor use in first- versus second-line for advanced breast cancer: A cost-effectiveness analysis of the phase 3 SONIA trial.

Authors: Wortelboer N Kent S Konings IR et al.

Source: European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2025 Dec 09; Vol. 231, pp. 116051. Date of Electronic Publication: 2025 Oct 25.

Publication Type: Journal Article; Clinical Trial, Phase III; Randomized Controlled Trial

Journal Info: Publisher: Elsevier Science Ltd Country of Publication: England NLM ID: 9005373 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-0852 (Electronic) Linking ISSN: 09598049 NLM ISO Abbreviation: Eur J Cancer Subsets: MEDLINE

MeSH Terms: Breast Neoplasms*/drug therapy , Breast Neoplasms*/economics , Breast Neoplasms*/pathology , Breast Neoplasms*/mortality , Cyclin-Dependent Kinase 6*/antagonists & inhibitors , Cyclin-Dependent Kinase 4*/antagonists & inhibitors , Protein Kinase Inhibitors*/economics , Protein Kinase Inhibitors*/therapeutic use , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use , Antineoplastic Combined Chemotherapy Protocols*/economics, Humans ; Female ; Cost-Benefit Analysis ; Quality-Adjusted Life Years ; Middle Aged ; Aged ; Cost-Effectiveness Analysis

Patient-reported outcomes with paclitaxel and ramucirumab switch maintenance in advanced gastroesophageal cancer: A secondary endpoint of the ARMANI phase 3 trial.

Authors: Cristarella E Ambrosini M Di Maio M et al.

Source: European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2025 Dec 09; Vol. 231, pp. 116060. Date of Electronic Publication: 2025 Oct 20.

Publication Type: Journal Article; Clinical Trial, Phase III; Randomized Controlled Trial; Multicenter Study

Journal Info: Publisher: Elsevier Science Ltd Country of Publication: England NLM ID: 9005373 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-0852 (Electronic) Linking ISSN: 09598049 NLM ISO Abbreviation: Eur J Cancer Subsets: MEDLINE

MeSH Terms: Paclitaxel*/administration & dosage , Paclitaxel*/adverse effects , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use , Antineoplastic Combined Chemotherapy Protocols*/adverse effects , Stomach Neoplasms*/drug therapy , Stomach Neoplasms*/pathology , Esophageal Neoplasms*/drug therapy , Esophageal Neoplasms*/pathology , Patient Reported Outcome Measures* , Esophagogastric Junction*/pathology , Esophagogastric Junction*/drug effects, Humans ; Ramucirumab ; Female ; Antibodies, Monoclonal, Humanized/administration & dosage ; Male ; Middle Aged ; Quality of Life ; Aged ; Adult ; Fluorouracil/administration & dosage ; Leucovorin/administration & dosage ; Maintenance Chemotherapy ; Progression-Free Survival

First-line pembrolizumab plus chemotherapy for advanced HER2-negative gastric or gastroesophageal junction adenocarcinoma: Health-related quality of life from the randomized phase III KEYNOTE-859 trial.

Authors: Lowery MA Wyrwicz LS Oh DY et al.

Source: European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2025 Dec 09; Vol. 231, pp. 115807. Date of Electronic Publication: 2025 Sep 20.

Publication Type: Journal Article; Randomized Controlled Trial; Clinical Trial, Phase III; Multicenter Study

Journal Info: Publisher: Elsevier Science Ltd Country of Publication: England NLM ID: 9005373 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-0852 (Electronic) Linking ISSN: 09598049 NLM ISO Abbreviation: Eur J Cancer Subsets: MEDLINE

MeSH Terms: Antibodies, Monoclonal, Humanized*/therapeutic use , Antibodies, Monoclonal, Humanized*/administration & dosage , Antibodies, Monoclonal, Humanized*/adverse effects , Quality of Life* , Stomach Neoplasms*/drug therapy , Stomach Neoplasms*/pathology , Adenocarcinoma*/drug therapy , Adenocarcinoma*/pathology , Esophagogastric Junction*/pathology , Esophagogastric Junction*/drug effects , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use , Antineoplastic Combined Chemotherapy Protocols*/adverse effects , Esophageal Neoplasms*/drug therapy , Esophageal Neoplasms*/pathology, Humans ; Female ; Male ; Middle Aged ; Receptor, ErbB-2/metabolism ; Aged ; Adult ; Patient Reported Outcome Measures ; Double-Blind Method

SCR Disease Name: Adenocarcinoma Of Esophagus

EORTC 1417 - REACTION: A phase II study of etoposide and cis/carboplatin with or without pembrolizumab in untreated extensive small cell lung cancer.

Authors: Menis J Greiller L Demontrond P et al.

Source: European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2025 Dec 09; Vol. 231, pp. 116059. Date of Electronic Publication: 2025 Oct 30.

Publication Type: Journal Article; Clinical Trial, Phase II; Randomized Controlled Trial; Multicenter Study

Journal Info: Publisher: Elsevier Science Ltd Country of Publication: England NLM ID: 9005373 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-0852 (Electronic) Linking ISSN: 09598049 NLM ISO Abbreviation: Eur J Cancer Subsets: MEDLINE

MeSH Terms: Antibodies, Monoclonal, Humanized*/administration & dosage , Antibodies, Monoclonal, Humanized*/adverse effects , Small Cell Lung Carcinoma*/drug therapy , Small Cell Lung Carcinoma*/pathology , Small Cell Lung Carcinoma*/mortality , Lung Neoplasms*/drug therapy , Lung Neoplasms*/pathology , Lung Neoplasms*/mortality , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use , Antineoplastic Combined Chemotherapy Protocols*/adverse effects, Humans ; Male ; Female ; Middle Aged ; Etoposide/administration & dosage ; Etoposide/adverse effects ; Aged ; Carboplatin/administration & dosage ; Carboplatin/adverse effects ; Cisplatin/administration & dosage ; Cisplatin/adverse effects ; Adult ; Neoplastic Cells, Circulating/pathology

Association of PET4 response with outcomes of BV-CHP vs CHOP in the ECHELON-2 trial in CD30+ peripheral T-cell lymphoma.

Authors: Iyer S Mehta-Shah N Advani R et al.

Source: Blood advances [Blood Adv] 2025 Dec 09; Vol. 9 (23), pp. 5976-5987.

Publication Type: Journal Article; Randomized Controlled Trial; Clinical Trial, Phase III; Multicenter Study

Journal Info: Publisher: American Society of Hematology Country of Publication: United States NLM ID: 101698425 Publication Model: Print Cited Medium: Internet ISSN: 2473-9537 (Electronic) Linking ISSN: 24739529 NLM ISO Abbreviation: Blood Adv Subsets: MEDLINE

MeSH Terms: Antineoplastic Combined Chemotherapy Protocols*/therapeutic use , Antineoplastic Combined Chemotherapy Protocols*/adverse effects , Lymphoma, T-Cell, Peripheral*/drug therapy , Lymphoma, T-Cell, Peripheral*/mortality , Lymphoma, T-Cell, Peripheral*/diagnostic imaging , Positron-Emission Tomography* , Ki-1 Antigen*/metabolism, Humans ; Prednisone/therapeutic use ; Prednisone/administration & dosage ; Doxorubicin/therapeutic use ; Doxorubicin/administration & dosage ; Vincristine/therapeutic use ; Vincristine/administration & dosage ; Cyclophosphamide/therapeutic use ; Cyclophosphamide/administration & dosage ; Female ; Male ; Middle Aged ; Treatment Outcome ; Brentuximab Vedotin/therapeutic use ; Brentuximab Vedotin/administration & dosage ; Aged ; Adult ; Fluorodeoxyglucose F18 ; Prognosis

SCR Protocol: CHOP protocol

Antitumor activity of the combination of vinorelbine and gemcitabine in patients with HR + /HER2- advanced breast cancer after CDK4/6 inhibitor.

Authors: Jara P Ariant M Jiménez R et al.

Source: Breast cancer research and treatment [Breast Cancer Res Treat] 2025 Dec 05; Vol. 215 (1), pp. 28. Date of Electronic Publication: 2025 Dec 05.

Publication Type: Journal Article

Journal Info: Publisher: Kluwer Academic Country of Publication: Netherlands NLM ID: 8111104 Publication Model: Electronic Cited Medium: Internet ISSN: 1573-7217 (Electronic) Linking ISSN: 01676806 NLM ISO Abbreviation: Breast Cancer Res Treat Subsets: MEDLINE

MeSH Terms: Breast Neoplasms*/drug therapy , Breast Neoplasms*/pathology , Breast Neoplasms*/mortality , Breast Neoplasms*/metabolism , Deoxycytidine*/analogs & derivatives , Deoxycytidine*/administration & dosage , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use , Antineoplastic Combined Chemotherapy Protocols*/adverse effects , Vinorelbine*/administration & dosage, Humans ; Female ; Gemcitabine ; Middle Aged ; Cyclin-Dependent Kinase 4/antagonists & inhibitors ; Retrospective Studies ; Cyclin-Dependent Kinase 6/antagonists & inhibitors ; Receptor, ErbB-2/metabolism ; Aged ; Adult ; Receptors, Progesterone/metabolism ; Receptors, Estrogen/metabolism ; Protein Kinase Inhibitors/therapeutic use ; Prognosis

Synergistic anticancer effects of doxorubicin in combination with tilorone in breast cancer.

Authors: Chhipa AS Gallicchio M Boscaro V et al.

Source: European journal of pharmacology [Eur J Pharmacol] 2025 Dec 05; Vol. 1008, pp. 178249. Date of Electronic Publication: 2025 Nov 01.

Publication Type: Journal Article

Journal Info: Publisher: Elsevier Science Country of Publication: Netherlands NLM ID: 1254354 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-0712 (Electronic) Linking ISSN: 00142999 NLM ISO Abbreviation: Eur J Pharmacol Subsets: MEDLINE

MeSH Terms: Doxorubicin*/pharmacology , Doxorubicin*/therapeutic use , Breast Neoplasms*/pathology , Breast Neoplasms*/drug therapy , Breast Neoplasms*/metabolism , Tilorone*/pharmacology , Tilorone*/therapeutic use , Antineoplastic Combined Chemotherapy Protocols*/pharmacology , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use , Antineoplastic Agents*/pharmacology, Drug Synergism ; Humans ; Female ; Animals ; Cell Line, Tumor ; Apoptosis/drug effects ; Cell Proliferation/drug effects ; Mice ; Cell Survival/drug effects ; Xenograft Model Antitumor Assays

Impact of immunochemotherapy regimens on outcomes of patients with primary mediastinal B-cell lymphoma in the IELSG37 trial.

Authors: Zucca E Ceriani L Ciccone G et al.

Source: Blood [Blood] 2025 Dec 04; Vol. 146 (23), pp. 2758-2764.

Publication Type: Journal Article; Multicenter Study; Clinical Trial, Phase III

Journal Info: Publisher: Elsevier Country of Publication: United States NLM ID: 7603509 Publication Model: Print Cited Medium: Internet ISSN: 1528-0020 (Electronic) Linking ISSN: 00064971 NLM ISO Abbreviation: Blood Subsets: MEDLINE

MeSH Terms: Antineoplastic Combined Chemotherapy Protocols*/therapeutic use , Antineoplastic Combined Chemotherapy Protocols*/administration & dosage , Mediastinal Neoplasms*/drug therapy , Mediastinal Neoplasms*/mortality , Mediastinal Neoplasms*/therapy , Lymphoma, B-Cell*/drug therapy , Lymphoma, B-Cell*/mortality , Lymphoma, B-Cell*/therapy , Immunotherapy*, Humans ; Male ; Female ; Middle Aged ; Doxorubicin/administration & dosage ; Doxorubicin/therapeutic use ; Rituximab/administration & dosage ; Rituximab/therapeutic use ; Vincristine/administration & dosage ; Vincristine/therapeutic use ; Cyclophosphamide/administration & dosage ; Cyclophosphamide/therapeutic use ; Prednisone/administration & dosage ; Prednisone/therapeutic use ; Aged ; Adult ; Treatment Outcome ; Young Adult ; Aged, 80 and over

Clinical Efficacy and Safety of Gemcitabine-Cisplatin Combination in Metastatic Gallbladder Cancer: A Prospective Study from North India.

Authors: Dewan A Talwar V Goel V et al.

Source: Journal of gastrointestinal cancer [J Gastrointest Cancer] 2025 Dec 03; Vol. 56 (1), pp. 233. Date of Electronic Publication: 2025 Dec 03.

Publication Type: Journal Article

Journal Info: Publisher: Springer Country of Publication: United States NLM ID: 101479627 Publication Model: Electronic Cited Medium: Internet ISSN: 1941-6636 (Electronic) NLM ISO Abbreviation: J Gastrointest Cancer Subsets: MEDLINE

MeSH Terms: Gallbladder Neoplasms*/drug therapy , Gallbladder Neoplasms*/pathology , Gallbladder Neoplasms*/mortality , Deoxycytidine*/analogs & derivatives , Deoxycytidine*/administration & dosage , Deoxycytidine*/adverse effects , Cisplatin*/administration & dosage , Cisplatin*/adverse effects , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use , Antineoplastic Combined Chemotherapy Protocols*/adverse effects, Humans ; Female ; Gemcitabine ; Male ; Middle Aged ; India/epidemiology ; Prospective Studies ; Aged ; Adult ; Prognosis

Comparison of Atezolizumab plus Aevacizumab and Atezolizumab plus Aabozantinib for advanced hepatocellular carcinoma: A cost-effectiveness analysis.

Authors: Xiang H She Z Wang L et al.

Source: PloS one [PLoS One] 2025 Dec 03; Vol. 20 (12), pp. e0337606. Date of Electronic Publication: 2025 Dec 03 (Print Publication: 2025).

Publication Type: Journal Article; Comparative Study

Journal Info: Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE

MeSH Terms: Carcinoma, Hepatocellular*/drug therapy , Carcinoma, Hepatocellular*/economics , Carcinoma, Hepatocellular*/pathology , Carcinoma, Hepatocellular*/mortality , Liver Neoplasms*/drug therapy , Liver Neoplasms*/economics , Liver Neoplasms*/pathology , Liver Neoplasms*/mortality , Antibodies, Monoclonal, Humanized*/economics , Antibodies, Monoclonal, Humanized*/therapeutic use , Antibodies, Monoclonal, Humanized*/administration & dosage , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use , Antineoplastic Combined Chemotherapy Protocols*/economics, Humans ; Cost-Benefit Analysis ; Quality-Adjusted Life Years ; Bevacizumab/economics ; Bevacizumab/therapeutic use ; Bevacizumab/administration & dosage ; Male ; Female ; Middle Aged ; Anilides/economics ; Anilides/therapeutic use ; Markov Chains ; Cost-Effectiveness Analysis ; Pyridines

Selection of isatuximab dosing regimen in pediatric patients with leukemia using population pharmacokinetics.

Authors: Brillac C Sémiond D Oprea C et al.

Source: Cancer chemotherapy and pharmacology [Cancer Chemother Pharmacol] 2025 Dec 03; Vol. 95 (1), pp. 116. Date of Electronic Publication: 2025 Dec 03.

Publication Type: Journal Article; Clinical Trial, Phase II

Journal Info: Publisher: Springer Verlag Country of Publication: Germany NLM ID: 7806519 Publication Model: Electronic Cited Medium: Internet ISSN: 1432-0843 (Electronic) Linking ISSN: 03445704 NLM ISO Abbreviation: Cancer Chemother Pharmacol Subsets: MEDLINE

MeSH Terms: Antibodies, Monoclonal, Humanized*/administration & dosage , Antibodies, Monoclonal, Humanized*/pharmacokinetics , Precursor Cell Lymphoblastic Leukemia-Lymphoma*/drug therapy , Models, Biological* , Antineoplastic Combined Chemotherapy Protocols*/administration & dosage , Antineoplastic Combined Chemotherapy Protocols*/pharmacokinetics , Leukemia, Myeloid, Acute*/drug therapy, Humans ; Infant ; Child, Preschool ; Male ; Female ; Child ; Dose-Response Relationship, Drug ; Computer Simulation ; Adolescent

Final results of JCOG0601 randomized trial of R-CHOP versus CHOP combined with dose-dense rituximab for diffuse large B-cell lymphoma.

Authors: Ohmachi K Kinoshita T Maruyama D et al.

Source: Japanese journal of clinical oncology [Jpn J Clin Oncol] 2025 Dec 03; Vol. 55 (12), pp. 1357-1364.

Publication Type: Journal Article; Randomized Controlled Trial; Clinical Trial, Phase II; Clinical Trial, Phase III; Multicenter Study

Journal Info: Publisher: Oxford University Press Country of Publication: England NLM ID: 0313225 Publication Model: Print Cited Medium: Internet ISSN: 1465-3621 (Electronic) Linking ISSN: 03682811 NLM ISO Abbreviation: Jpn J Clin Oncol Subsets: MEDLINE

MeSH Terms: Lymphoma, Large B-Cell, Diffuse*/drug therapy , Lymphoma, Large B-Cell, Diffuse*/pathology , Lymphoma, Large B-Cell, Diffuse*/mortality , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use , Antineoplastic Combined Chemotherapy Protocols*/adverse effects , Antineoplastic Combined Chemotherapy Protocols*/administration & dosage, Humans ; Rituximab/administration & dosage ; Rituximab/therapeutic use ; Rituximab/adverse effects ; Cyclophosphamide/administration & dosage ; Cyclophosphamide/adverse effects ; Cyclophosphamide/therapeutic use ; Vincristine/adverse effects ; Vincristine/administration & dosage ; Vincristine/therapeutic use ; Doxorubicin/adverse effects ; Doxorubicin/administration & dosage ; Doxorubicin/therapeutic use ; Middle Aged ; Prednisone/adverse effects ; Prednisone/administration & dosage ; Prednisone/therapeutic use ; Adult ; Male ; Female ; Aged ; Young Adult

Efficacy and safety of a reduced starting dose of cabozantinib (20 mg) plus nivolumab for renal cell carcinoma in real-world practice.

Authors: Sazuka T Watanabe Y Yokochi F et al.

Source: Japanese journal of clinical oncology [Jpn J Clin Oncol] 2025 Dec 03; Vol. 55 (12), pp. 1391-1396.

Publication Type: Journal Article

Journal Info: Publisher: Oxford University Press Country of Publication: England NLM ID: 0313225 Publication Model: Print Cited Medium: Internet ISSN: 1465-3621 (Electronic) Linking ISSN: 03682811 NLM ISO Abbreviation: Jpn J Clin Oncol Subsets: MEDLINE

MeSH Terms: Carcinoma, Renal Cell*/drug therapy , Carcinoma, Renal Cell*/pathology , Anilides*/administration & dosage , Anilides*/adverse effects , Nivolumab*/administration & dosage , Nivolumab*/adverse effects , Pyridines*/administration & dosage , Pyridines*/adverse effects , Kidney Neoplasms*/drug therapy , Kidney Neoplasms*/pathology , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use , Antineoplastic Combined Chemotherapy Protocols*/adverse effects , Antineoplastic Combined Chemotherapy Protocols*/administration & dosage, Humans ; Male ; Female ; Aged ; Retrospective Studies ; Aged, 80 and over ; Middle Aged ; Treatment Outcome